EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma

Steven M Monda iD, Benjamin W Carney, Allison M May, Shuchi Gulati, Simpa S Salami iD, Thenappan Chandrasekar, Evan T Keller, Nicolai A Huebner, Ganesh S Palapattu, Marc A Dall'Era iD

BJU International · 2025

DOI: 10.1111/bju.16527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Steven M Monda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urologic Surgery, UC Davis, Sacramento, CA, USA. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, the Clark Family Fellowship in Kidney Cancer Research, Steven Monda is supported by the National Institutes of Health/National Cancer Institute Advanced Training in Urologic Oncology Grant (T32 CA180984) and the Cl….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the distribution of key mutations across tumour sizes in clear‐cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs. Patient and Methods The distribution of mutations ( VHL , PBRM1 , SETD2 , BAP1 and CDKN2A loss) across tumour sizes was assessed in 1039 ccRCCs treated with nephrectomy in cohorts obtained from the Tracking Cancer Evolution (TRACERx), The Cancer Genome Atlas (TCGA) and the Cancer Genomics of the Kidney (CAGEKID) projects. Logistic regression was used to model the presence of each mutation against size. In our secondary analysis, we assessed a subset of ccRCCs ≤7 cm for associations of key aggressive mutations ( SETD2 , BAP1 , and CDKN2A loss) with metastasis, invasive disease and overall survival, while controlling for size. A subset of localised tumours ≤7 cm was also used to assess associations with recurrence after nephrectomy.

Results

On logistic regression, each 1‐cm increase in tumour size was associated with aggressive mutations, SETD2 , BAP1 , and CDKN2A loss, at odds ratios (ORs) of 1.09, 1.10 and 1.19 ( P < 0.001), whereas no significant association was observed between tumour size and PBRM1 (OR 1.02; P = 0.23). VHL was mildly negatively associated with a 1‐cm increase in size (OR 0.95; P = 0.01). Among tumours ≤7 cm, SETD2 and CDKN2A loss were associated with metastatic disease at ORs of 3.86 and 3.84 ( P < 0.05) while controlling for tumour size. CDKN2A loss was associated with worse overall survival, with a hazard ratio (HR) of 2.19 ( P = 0.03). Among localised tumours ≤7 cm, SETD2 was associated with worse recurrence‐free survival (HR 2.00; P = 0.03).

Conclusion

Large and small ccRCCs are genomically different. Aggressive mutations, namely, SETD2 , BAP1 , and CDKN2A loss, are rarely observed in small ccRCCs and are observed more frequently in larger tumours. However, when present in tumours ≤7 cm, SETD2 mutations and CDKN2A loss were still independently associated with invasive disease, metastasis, worse survival, and recurrence after resection, after controlling for size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellMutationHumansMaleFemaleUbiquitin ThiolesteraseMiddle AgedHistone-Lysine N-MethyltransferaseAgedTumor Suppressor ProteinsPrognosisNephrectomyTumor BurdenCyclin-Dependent Kinase Inhibitor p16DNA-Binding ProteinsTranscription Factors

Stichwörter der Autor:innen

bap1cdkn2aclear‐cell renal cell carcinomagenomicsrenal cell carcinomasetd2survivaltcgatracerxtumour size

Substanzen

Ubiquitin ThiolesteraseBAP1 protein, humanSETD2 protein, humanHistone-Lysine N-MethyltransferaseTumor Suppressor ProteinsPBRM1 protein, humanCyclin-Dependent Kinase Inhibitor p16DNA-Binding ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Urologic Surgery, UC Davis, Sacramento, CA, USA.
  • Department of Radiology, UC Davis, Sacramento, CA, USA.
  • Department of Urology, University of Michigan, Ann Arbor, MI, USA.
  • Division of Hematology and Oncology, UC Davis, Sacramento, CA, USA.
  • Department of Urology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Steven M Monda, Simpa S Salami, Marc A Dall'Era

Förderung

  • NCI NIH HHS
  • the Clark Family Fellowship in Kidney Cancer Research
  • Steven Monda is supported by the National Institutes of Health/National Cancer Institute Advanced Training in Urologic Oncology Grant (T32 CA180984) and the Cl…

Zitieren

APA

Monda, S. M., Carney, B. W., May, A. M., Gulati, S., Salami, S. S., Chandrasekar, T., Keller, E. T., Huebner, N. A., Palapattu, G. S., & Dall'Era, M. A. (2025). Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma. BJU International. https://doi.org/10.1111/bju.16527

Vancouver

Monda SM, Carney BW, May AM, Gulati S, Salami SS, Chandrasekar T, et al. Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma. BJU International. 2025. doi:10.1111/bju.16527

BibTeX
@article{Monda2025,
  author = {Monda, Steven M and Carney, Benjamin W and May, Allison M and Gulati, Shuchi and Salami, Simpa S and Chandrasekar, Thenappan and Keller, Evan T and Huebner, Nicolai A and Palapattu, Ganesh S and Dall'Era, Marc A},
  title = {Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16527}
}
Kostenlos starten →